259 related articles for article (PubMed ID: 21940710)
41. Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data.
Crisman TJ; Parker CN; Jenkins JL; Scheiber J; Thoma M; Kang ZB; Kim R; Bender A; Nettles JH; Davies JW; Glick M
J Chem Inf Model; 2007; 47(4):1319-27. PubMed ID: 17608469
[TBL] [Abstract][Full Text] [Related]
42. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease.
Bodenreider C; Beer D; Keller TH; Sonntag S; Wen D; Yap L; Yau YH; Shochat SG; Huang D; Zhou T; Caflisch A; Su XC; Ozawa K; Otting G; Vasudevan SG; Lescar J; Lim SP
Anal Biochem; 2009 Dec; 395(2):195-204. PubMed ID: 19682971
[TBL] [Abstract][Full Text] [Related]
43. A bioluminogenic HDAC activity assay: validation and screening.
Halley F; Reinshagen J; Ellinger B; Wolf M; Niles AL; Evans NJ; Kirkland TA; Wagner JM; Jung M; Gribbon P; Gul S
J Biomol Screen; 2011 Dec; 16(10):1227-35. PubMed ID: 21832257
[TBL] [Abstract][Full Text] [Related]
44. An Analysis of Different Components of a High-Throughput Screening Library.
Saha A; Varghese T; Liu A; Allen SJ; Mirzadegan T; Hack MD
J Chem Inf Model; 2018 Oct; 58(10):2057-2068. PubMed ID: 30204440
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of division-arrested cells for cell-based high-throughput screening and profiling.
Digan ME; Pou C; Niu H; Zhang JH
J Biomol Screen; 2005 Sep; 10(6):615-23. PubMed ID: 16103416
[TBL] [Abstract][Full Text] [Related]
46. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format.
Hashimoto J; Watanabe T; Seki T; Karasawa S; Izumikawa M; Seki T; Iemura S; Natsume T; Nomura N; Goshima N; Miyawaki A; Takagi M; Shin-Ya K
J Biomol Screen; 2009 Sep; 14(8):970-9. PubMed ID: 19641222
[TBL] [Abstract][Full Text] [Related]
47. False positives in the early stages of drug discovery.
Sink R; Gobec S; Pečar S; Zega A
Curr Med Chem; 2010; 17(34):4231-55. PubMed ID: 20939815
[TBL] [Abstract][Full Text] [Related]
48. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
Roy A; McDonald PR; Sittampalam S; Chaguturu R
Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
[TBL] [Abstract][Full Text] [Related]
49. Substrate screening of protein kinases: detection methods and combinatorial peptide libraries.
Kim M; Shin DS; Kim J; Lee YS
Biopolymers; 2010; 94(6):753-62. PubMed ID: 20564046
[TBL] [Abstract][Full Text] [Related]
50. Hypothesis-driven screening.
Schopfer U; Engeloch C; Höhn F; Mees H; Leeds J; Glickman F; Scheel G; Ferrand S; Fekkes P; Pfeifer M
Methods Mol Biol; 2009; 575():297-316. PubMed ID: 19727621
[TBL] [Abstract][Full Text] [Related]
51. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
52. Concise review: a high-content screening approach to stem cell research and drug discovery.
Xia X; Wong ST
Stem Cells; 2012 Sep; 30(9):1800-7. PubMed ID: 22821636
[TBL] [Abstract][Full Text] [Related]
53. Extending matrix-assisted laser desorption/ionization triple quadrupole mass spectrometry enzyme screening assays to targets with small molecule substrates.
Rathore R; Corr JJ; Lebre DT; Seibel WL; Greis KD
Rapid Commun Mass Spectrom; 2009 Oct; 23(20):3293-300. PubMed ID: 19757451
[TBL] [Abstract][Full Text] [Related]
54. [High-throughput Screening Technology for Selective Inhibitors of Transporters and Its Application in Drug Discovery].
Motoyaji T
Yakugaku Zasshi; 2021; 141(4):511-515. PubMed ID: 33790118
[TBL] [Abstract][Full Text] [Related]
55. Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy.
Bakken GA; Bell AS; Boehm M; Everett JR; Gonzales R; Hepworth D; Klug-McLeod JL; Lanfear J; Loesel J; Mathias J; Wood TP
J Chem Inf Model; 2012 Nov; 52(11):2937-49. PubMed ID: 23062111
[TBL] [Abstract][Full Text] [Related]
56. An integrated bioanalytical platform for supporting high-throughput serum protein binding screening.
Zhang J; Shou WZ; Vath M; Kieltyka K; Maloney J; Elvebak L; Stewart J; Herbst J; Weller HN
Rapid Commun Mass Spectrom; 2010 Dec; 24(24):3593-601. PubMed ID: 21080511
[TBL] [Abstract][Full Text] [Related]
57. A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKbeta-NEMO interaction.
Gotoh Y; Nagata H; Kase H; Shimonishi M; Ido M
Anal Biochem; 2010 Oct; 405(1):19-27. PubMed ID: 20522330
[TBL] [Abstract][Full Text] [Related]
58. Virtual screening strategies in drug discovery.
McInnes C
Curr Opin Chem Biol; 2007 Oct; 11(5):494-502. PubMed ID: 17936059
[TBL] [Abstract][Full Text] [Related]
59. Review article: high-throughput affinity-based technologies for small-molecule drug discovery.
Zhu Z; Cuozzo J
J Biomol Screen; 2009 Dec; 14(10):1157-64. PubMed ID: 19822881
[TBL] [Abstract][Full Text] [Related]
60. Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors.
Kashem MA; Nelson RM; Yingling JD; Pullen SS; Prokopowicz AS; Jones JW; Wolak JP; Rogers GR; Morelock MM; Snow RJ; Homon CA; Jakes S
J Biomol Screen; 2007 Feb; 12(1):70-83. PubMed ID: 17166826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
